Gumarontinib

Gumarontinib
Clinical data
Other names	Glumetinib; SCC244; SC-C244
Routes of; administration	Oral
Legal status
Legal status	Rx in China;
Identifiers
	IUPAC name 6-(1-Methylpyrazol-4-yl)-1-[6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl]sulfonylpyrazolo[4,3-b]pyridine;
CAS Number	1642581-63-2;
PubChem CID	117797905;
DrugBank	DB15630;
ChemSpider	68006902;
UNII	7JTT036WGX;
ChEMBL	ChEMBL4594400;
Chemical and physical data
Formula	C21H17N9O2S
Molar mass	459.49 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C=C(C=N1)C2=CN3C(=NC=C3S(=O)(=O)N4C5=C(C=N4)N=CC(=C5)C6=CN(N=C6)C)C=C2;
	InChI InChI=1S/C21H17N9O2S/c1-27-11-16(7-24-27)14-3-4-20-23-10-21(29(20)13-14)33(31,32)30-19-5-15(6-22-18(19)9-26-30)17-8-25-28(2)12-17/h3-13H,1-2H3; Key:RYBLECYFLJXEJX-UHFFFAOYSA-N;

Gumarontinib is a pharmaceutical drug used for the treatment of cancer. In China, it was conditionally approved in 2023 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation.^[1]

Gumarontinib is a selective mesenchymal–epithelial transition (MET) inhibitor.^[2]

References

^ "NMPA conditionally approves gumarontinib for treatment of non-small cell lung cancer with MET Exon 14 skipping mutation". ecancer.org. 10 March 2023.
^ Yu Y, Zhou J, Li X, Goto K, Min X, Nishino K, et al. (May 2023). "Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial". eClinicalMedicine. 59: 101952. doi:10.1016/j.eclinm.2023.101952. PMC 10121392. PMID 37096188.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] "NMPA conditionally approves gumarontinib for treatment of non-small cell lung cancer with MET Exon 14 skipping mutation". ecancer.org. 10 March 2023.

[2] Yu Y, Zhou J, Li X, Goto K, Min X, Nishino K, et al. (May 2023). "Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial". eClinicalMedicine. 59: 101952. doi:10.1016/j.eclinm.2023.101952. PMC 10121392. PMID 37096188.

[1]

[2]